Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
BioPharma Dive3h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
BMO raises Vertex stock price target to $545 from $520
BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the ...
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
PBS6h
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...
FDA approves first non-addictive pain medication
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
FDA approves new type of non-opioid pain medication in two decades
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin, the first of its kind in 20 years.
Forbes Daily: DeepSeek’s AI Model Raises National Security Concerns
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.
News Highlights: Top Company News of the Day - Friday at 3 AM ET
The Japanese conglomerate is in talks to spend up to $43 billion to boost the ChatGPT developer. Novartis expects profit and sales to grow further this year after beating analysts' expectations, ...
FDA Approves Non-Opioid Painkiller With No Addiction Risk
The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the ...